CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 36
- Registration Number
- NCT02119234
- Locations
- 🇵🇱
Medical University in Lodz, Lodz, Ul. Kopcińskiego 22, Poland
Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT02119247
- Locations
- 🇧🇪
SGS CPU Antwerpen ZNA Stuivenberg, Antwerpen, Belgium
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.
- Conditions
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 42
- Registration Number
- NCT02040597
- Locations
- 🇵🇱
Medical University in Lodz, Lodz, Ul. Kopcińskiego 22, Poland
🇵🇱Biovirtus Research Site, Nadarzyn, Mokra 7, Poland
An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 72
- Registration Number
- NCT02018549
- Locations
- 🇮🇹
Ospedale di Parma, Parma, Italy
A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 49
- Registration Number
- NCT02000609
- Locations
- 🇬🇧
Medicine Evaluation Unit, Manchester, United Kingdom
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT01938547
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Stanford Medical Center, Stanford, California, United States
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
- Conditions
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1368
- Registration Number
- NCT01917331
- Locations
- 🇭🇺
Dr Beatrix BALINT, Szeged, Hungary
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3686
- Registration Number
- NCT01911364
- Locations
- 🇮🇹
Azienda Ospedaliera Perugia, Perugia, Italy
🇩🇪Institut für klinische Forschung, Hessen, Germany
🇭🇺Csongrád Megyei Mellkasi Betegségek Szakkórháza, Szeged, Hungary
Lamazym Aftercare Study
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 8
- Registration Number
- NCT01908725
- Locations
- 🇩🇰
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 13
- Registration Number
- NCT01908712
- Locations
- 🇫🇷
Hôpital Femme Mére Enfant - CHU de Lyon, Bron, France